查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1351092

到 2030 年皰疹性皮膚炎市場預測：按治療、給藥途徑、配銷通路和地區進行的全球分析

Dermatitis Herpetiformis Market Forecasts to 2030 - Global Analysis By Treatment (Therapeutics, Dietary and Other Treatments), Route of Administration, Distribution channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預測期內全球皰疹性皮膚炎市場的年複合成長率為 9.2%。

皰疹性皮膚炎是一種慢性自體免疫疾病，其特徵是劇烈搔癢和灼熱感，導致皮膚出現皮疹。它經常發生在患有麩質敏感性腸病或乳糜瀉的患者中，乳糜瀉是一種麩質消化障礙。從流行病學角度來看，這是一種罕見疾病，主要罹患年輕人。最終的治療方法是嚴格的無麩質飲食，可以在幾個月內改善皮膚，但無麩質飲食可能需要幾年的時間才能成為唯一的治療方法。

據 DermNet NZ 稱，它可能影響 15 歲至 40 歲之間的患者。男性比女性更容易罹患。

皰疹性皮膚炎增加

皰疹性皮膚炎伴隨劇烈搔癢。這是一種長期的自體免疫疾病，會導致嚴重搔癢、潮熱和皮疹。患有乳糜瀉、麩質敏感腸病和麩質消化問題的人更有可能患上這種疾病。流行病學表明，這是一種罕見疾病，主要影響年輕人。同樣，由於尋找皰疹性皮膚炎治療方法的投資增加，預計市場將快速成長。

與治療相關的併發症

然而，患者可能會遇到牙齒問題。此外，皰疹性皮膚炎可能被誤認為是疥瘡。由於藥物治療，患者還患有貧血、骨質疏鬆症、1 型糖尿病和甲狀腺問題。儘管有些問題很少見，但它們也會引起神經症狀，例如共濟失調和神經病變。使用氨苯碸的負面影響，例如血紅蛋白減少，可能導致喉嚨痛、昏厥、頭暈，甚至某些人的肝臟病變，是限制市場擴張的另一個原因。

有利的贖回程序

新興市場皮膚炎罹患率的增加和有利的報銷政策預計也將促進市場成長率。此外，配合措施為提供更好、更經濟的治療方法以及提高對該疾病治療方案的認知而採取的舉措預計也將影響全球市場。

高成本

這個市場受到高昂的治療費用的嚴重限制。患者可能會承受長期照護費用的負擔，包括處方藥物和健康檢查，這可能會阻止他們獲得最佳的治療選擇。此外，預計該行業將受到通用治療方案的出現和嚴格的法規限制的重大影響。

COVID-19 的影響：

冠狀病毒危機以及隨後世界多個國家的封鎖對領先的尿素循環障礙治療公司產生了財務影響。此外，私人醫療保健部門是受疫情影響最嚴重的領域之一。疫情對全球研發、生產和藥品供應市場產生了負面影響。此外，由於一些國家政府關門，疫情影響了全球各企業的製藥業擴張。

在預測期內，外用藥物領域預計將是最大的。

預計外用藥物細分市場將成為預測期內最大的細分市場。外用處方藥通常是皰疹性皮膚炎的第一線治療方法。這些藥物有乳液、霜劑、栓劑等形式。這種即時預計將導致快速收購和大量行動保留，從而推動細分市場的成長。

預計零售藥局領域在預測期內年複合成長率最高

零售藥房領域預計在預測期內年複合成長率最高。治療皰疹性皮膚炎的藥物通常可以在零售藥局以非專利藥的形式購買。零售藥局也提供便利的服務，例如家庭藥物遞送和取得各種藥物。此外，由於忙碌的生活方式和緊張的工作日程，消費者對快速獲取產品的需求預計將推動脂質調節劑市場的擴張。

比最大的地區

由於遺傳疾病和基因突變相關疾病的增加，預計北美在預測期內將佔據最大的市場佔有率。這主要是由於異位性皮膚炎患病不斷上升、患者群體的治療意識較高以及異位性皮膚炎行業的進步。此外，製藥公司加大開發新藥配合措施、技術進步和高採用率也正在幫助患者做出更好的治療選擇。

複合年複合成長率最高的地區：

由於患者意識較低，亞太地區預計在預測期內將維持最高的年複合成長率。這是由於快速發展的醫療技術、大量的患者以及不斷上漲的醫療成本。由於各國研發項目的增加、醫療基礎設施的發展、對先進技術外科手術的接受度不斷提高以及政府舉措的不斷增加，預計市場在預測期內將呈現成長。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球皰疹性皮膚炎市場：依治療分類

  • 治療
    • 局部皮質類固醇
    • 磺胺類藥物
    • 氨苯碸
  • 用餐
    • 即食食品
    • 烘焙食品
    • 義大利麵
  • 其他治療

第6章 全球皰疹性皮膚炎市場：依給藥途徑

  • 外用
  • 口服

第7章 全球皰疹性皮膚炎市場：按配銷通路

  • 零售店
  • 電子商務
  • 藥局
  • 其他配銷通路

第8章 全球皰疹性皮膚炎市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Allergan
  • 3B scientific
  • Acros Organics
  • Aidance Scientific
  • AlliChem
  • Aidance Scientific
  • Canyon Bakehouse
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • HBC Chem
  • Ivy Fine chemicals
  • Nostrum Laboratories Inc.
  • Pfizer Inc.
  • Shingles Skincare
  • AbbVie Inc.
  • Waterstone Technology
Product Code: SMRC23779

According to Stratistics MRC, the Global Dermatitis Herpetiformis Market is growing at a CAGR of 9.2% during the forecast period. Dermatitis Herpetiformis is a chronic autoimmune illness marked by strong itching and burning sensations, resulting in a skin rash. People with celiac disease, a gluten-sensitive enteropathy or anomaly in gluten digestion, frequently have it. Epidemiologically speaking, it is a rare disease that primarily affects young adults. The final course of treatment entails a strict gluten-free diet, with which skin improvement is anticipated in a few months, though it might take years for the gluten-free diet to be the only course of treatment.

According to the DermNet NZ organisation, Patients between the ages of 15 and 40 may be affected. Males are more susceptible to the condition than females.

Market Dynamics:

Driver:

Increasing incidence of dermatitis herpetiformis

Patients with dermatitis herpetiformis have severe itching. It is a long-term autoimmune condition that results in intense itchiness, burning, and skin rashes. People with celiac disease, gluten-sensitive enteropathy, or issues with gluten digestion are more likely to experience it. It is a rare disease that mostly affects young adults, according to epidemiology. Again, due to increasing investments in finding treatments for dermatitis herpetiformis, the market is expected to grow rapidly.

Restraint:

Complications associated with treatment

Patients could, however, experience dental issues. Additionally, it's possible that dermatitis herpetiformis will be mistaken for scabies. Due to therapeutic medications, the patient also suffers anemia, osteoporosis, Type 1 diabetes, and thyroid issues. Although some of the problems are uncommon, there is a potential that they could result in neurological conditions including ataxia and neuropathy. The negative consequences of dapsone use, such as a drop in hemoglobin, which can cause sore throats, fainting spells, dizziness, and even liver problems in some people, are another reason that can limit market expansion.

Opportunity:

Advantageous reimbursement procedures

The increasing incidence of dermatitis and the favorable reimbursement policies in developing nations are also anticipated to contribute to the market growth rate. Additionally, it is anticipated that increased government efforts to provide better and more economical care as well as increased awareness of the disease's treatment options will have an impact on the global market.

Threat:

High cost

The market is severely constrained by the treatment's high cost. Patients may be burdened by the costs of long-term care, which may include prescription drugs and wellness visits, and this may prevent them from accessing the best possible treatment options. Furthermore, it is projected that the industry will be significantly impacted by the advent of generic treatment options and strict regulatory constraints.

COVID-19 Impact:

The corona virus crisis and subsequent lockdown in several nations worldwide have financially impacted major urea cycle disorders treatment firms. Moreover, the private healthcare sector is one of the areas that the pandemic has damaged the most. The pandemic has had a detrimental impact on the worldwide market regarding research and development, production, and pharmaceutical supply. In addition, due to government lockdowns in some countries, the pandemic has impacted the expansion of pharmaceutical industries of various corporations worldwide.

The topical segment is expected to be the largest during the forecast period

The topical segment is expected to be the largest during the forecast period. A topical prescription drug is usually the first line of treatment for dermatitis herpetiformis. These can be in the shape of lotions, creams, suppositories, and other things. Such immediacy leads to speedy acquisition and substantial behaviour maintenance, which is expected to drive segment growth in the market.

The retail pharmacies segment is expected to have the highest CAGR during the forecast period

The retail pharmacies segment is expected to have the highest CAGR during the forecast period. Medication for dermatitis herpetiformis is commonly available as a generic pharmaceutical in retail pharmacies. In addition, retail pharmacies provide convenient services such as medicine delivery to your home and the availability of a wide range of drugs and medicines. Furthermore, lipid-regulating medicines market expansion is expected to be boosted by consumer demand for quick availability of products due to busy lifestyles and stressful work schedules.

Region with largest share:

North America is projected to hold the largest market share during the forecast period, owing to increased inherited and genetic mutation related disorders. This is primarily attributed to increasing prevalence of atopic dermatitis, high treatment awareness among the patient population, and advancement in atopic dermatitis industry. The increasing initiatives taken by the pharmaceutical organizations to generate novel drugs, technological advancements and high adoption rate, which will help patients opt for better treatment.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period, due to the low awareness among patients. This is attributed to strong presence of rapidly developing healthcare technology, huge patient population and rise in healthcare expenditure. With the rise in R&D projects in countries, developing medical infrastructure, rise in acceptance of technologically advanced surgical procedures and rising government initiatives, the market is expected to witness growth over forecast period.

Key players in the market:

Some of the key players in Dermatitis Herpetiformis market include: Allergan, 3B scientific, Acros Organics, Aidance Scientific, AlliChem, Aidance Scientific, Canyon Bakehouse, GlaxoSmithKline Pharmaceuticals Ltd., HBC Chem, Ivy Fine chemicals, Nostrum Laboratories Inc., Pfizer Inc., Shingles Skincare, AbbVie Inc. and Waterstone Technology.

Key Developments:

In May 2023, AbbVie's aesthetics unit is growing its product catalog once again with a new FDA approval. The product, called Skinvive, nabbed an FDA nod this week and falls within Allergan's Juvederm dermal filler collection.

In May 2022, Sidekick and Pfizer launch digital therapeutics solution for Atopic Dermatitis. The solution will be rolled-out in the UK first, followed by Belgium, Norway, the Netherlands, Sweden, France, Ireland, and Japan.

In January 2022, AbbVie Inc. announced that the US FDA has approved RINVOQ (upadacitinib) for the treatment of severe atopic dermatitis in children and adults 12 years of age and older. RINVOQ is recommended for patients who have not responded to previous injection or tablet treatments.

Treatments Covered:

  • Therapeutics
  • Dietary
  • Other Treatments

Route of Administrations Covered:

  • Topical
  • Oral

Distribution channels Covered:

  • Retail stores
  • E-Commerce
  • Pharmacies
  • Other Distribution channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Dermatitis Herpetiformis Market, By Treatment

  • 5.1 Introduction
  • 5.2 Therapeutics
    • 5.2.1 Topical Corticosteroids
    • 5.2.2 Sulfa Drugs
    • 5.2.3 Dapsone
  • 5.3 Dietary
    • 5.3.1 Ready-to-eat Meals
    • 5.3.2 Bakery Products
    • 5.3.3 Pasta
  • 5.4 Other Treatments

6 Global Dermatitis Herpetiformis Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Topical
  • 6.3 Oral

7 Global Dermatitis Herpetiformis Market, By Distribution channel

  • 7.1 Introduction
  • 7.2 Retail stores
  • 7.3 E-Commerce
  • 7.4 Pharmacies
  • 7.5 Other Distribution channels

8 Global Dermatitis Herpetiformis Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Allergan
  • 10.2 3B scientific
  • 10.3 Acros Organics
  • 10.4 Aidance Scientific
  • 10.5 AlliChem
  • 10.6 Aidance Scientific
  • 10.7 Canyon Bakehouse
  • 10.8 GlaxoSmithKline Pharmaceuticals Ltd.
  • 10.9 HBC Chem
  • 10.10 Ivy Fine chemicals
  • 10.11 Nostrum Laboratories Inc.
  • 10.12 Pfizer Inc.
  • 10.13 Shingles Skincare
  • 10.14 AbbVie Inc.
  • 10.15 Waterstone Technology

List of Tables

  • Table 1 Global Dermatitis Herpetiformis Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Dermatitis Herpetiformis Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 3 Global Dermatitis Herpetiformis Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 4 Global Dermatitis Herpetiformis Market Outlook, By Topical Corticosteroids (2021-2030) ($MN)
  • Table 5 Global Dermatitis Herpetiformis Market Outlook, By Sulfa Drugs (2021-2030) ($MN)
  • Table 6 Global Dermatitis Herpetiformis Market Outlook, By Dapsone (2021-2030) ($MN)
  • Table 7 Global Dermatitis Herpetiformis Market Outlook, By Dietary (2021-2030) ($MN)
  • Table 8 Global Dermatitis Herpetiformis Market Outlook, By Ready-to-eat Meals (2021-2030) ($MN)
  • Table 9 Global Dermatitis Herpetiformis Market Outlook, By Bakery Products (2021-2030) ($MN)
  • Table 10 Global Dermatitis Herpetiformis Market Outlook, By Pasta (2021-2030) ($MN)
  • Table 11 Global Dermatitis Herpetiformis Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 12 Global Dermatitis Herpetiformis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 13 Global Dermatitis Herpetiformis Market Outlook, By Topical (2021-2030) ($MN)
  • Table 14 Global Dermatitis Herpetiformis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 15 Global Dermatitis Herpetiformis Market Outlook, By Distribution channel (2021-2030) ($MN)
  • Table 16 Global Dermatitis Herpetiformis Market Outlook, By Retail stores (2021-2030) ($MN)
  • Table 17 Global Dermatitis Herpetiformis Market Outlook, By E-Commerce (2021-2030) ($MN)
  • Table 18 Global Dermatitis Herpetiformis Market Outlook, By Pharmacies (2021-2030) ($MN)
  • Table 19 Global Dermatitis Herpetiformis Market Outlook, By Other Distribution channels (2021-2030) ($MN)
  • Table 20 North America Dermatitis Herpetiformis Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Dermatitis Herpetiformis Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 22 North America Dermatitis Herpetiformis Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 23 North America Dermatitis Herpetiformis Market Outlook, By Topical Corticosteroids (2021-2030) ($MN)
  • Table 24 North America Dermatitis Herpetiformis Market Outlook, By Sulfa Drugs (2021-2030) ($MN)
  • Table 25 North America Dermatitis Herpetiformis Market Outlook, By Dapsone (2021-2030) ($MN)
  • Table 26 North America Dermatitis Herpetiformis Market Outlook, By Dietary (2021-2030) ($MN)
  • Table 27 North America Dermatitis Herpetiformis Market Outlook, By Ready-to-eat Meals (2021-2030) ($MN)
  • Table 28 North America Dermatitis Herpetiformis Market Outlook, By Bakery Products (2021-2030) ($MN)
  • Table 29 North America Dermatitis Herpetiformis Market Outlook, By Pasta (2021-2030) ($MN)
  • Table 30 North America Dermatitis Herpetiformis Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 31 North America Dermatitis Herpetiformis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 32 North America Dermatitis Herpetiformis Market Outlook, By Topical (2021-2030) ($MN)
  • Table 33 North America Dermatitis Herpetiformis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 34 North America Dermatitis Herpetiformis Market Outlook, By Distribution channel (2021-2030) ($MN)
  • Table 35 North America Dermatitis Herpetiformis Market Outlook, By Retail stores (2021-2030) ($MN)
  • Table 36 North America Dermatitis Herpetiformis Market Outlook, By E-Commerce (2021-2030) ($MN)
  • Table 37 North America Dermatitis Herpetiformis Market Outlook, By Pharmacies (2021-2030) ($MN)
  • Table 38 North America Dermatitis Herpetiformis Market Outlook, By Other Distribution channels (2021-2030) ($MN)
  • Table 39 Europe Dermatitis Herpetiformis Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Dermatitis Herpetiformis Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 41 Europe Dermatitis Herpetiformis Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 42 Europe Dermatitis Herpetiformis Market Outlook, By Topical Corticosteroids (2021-2030) ($MN)
  • Table 43 Europe Dermatitis Herpetiformis Market Outlook, By Sulfa Drugs (2021-2030) ($MN)
  • Table 44 Europe Dermatitis Herpetiformis Market Outlook, By Dapsone (2021-2030) ($MN)
  • Table 45 Europe Dermatitis Herpetiformis Market Outlook, By Dietary (2021-2030) ($MN)
  • Table 46 Europe Dermatitis Herpetiformis Market Outlook, By Ready-to-eat Meals (2021-2030) ($MN)
  • Table 47 Europe Dermatitis Herpetiformis Market Outlook, By Bakery Products (2021-2030) ($MN)
  • Table 48 Europe Dermatitis Herpetiformis Market Outlook, By Pasta (2021-2030) ($MN)
  • Table 49 Europe Dermatitis Herpetiformis Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 50 Europe Dermatitis Herpetiformis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 51 Europe Dermatitis Herpetiformis Market Outlook, By Topical (2021-2030) ($MN)
  • Table 52 Europe Dermatitis Herpetiformis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 53 Europe Dermatitis Herpetiformis Market Outlook, By Distribution channel (2021-2030) ($MN)
  • Table 54 Europe Dermatitis Herpetiformis Market Outlook, By Retail stores (2021-2030) ($MN)
  • Table 55 Europe Dermatitis Herpetiformis Market Outlook, By E-Commerce (2021-2030) ($MN)
  • Table 56 Europe Dermatitis Herpetiformis Market Outlook, By Pharmacies (2021-2030) ($MN)
  • Table 57 Europe Dermatitis Herpetiformis Market Outlook, By Other Distribution channels (2021-2030) ($MN)
  • Table 58 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 60 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 61 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Topical Corticosteroids (2021-2030) ($MN)
  • Table 62 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Sulfa Drugs (2021-2030) ($MN)
  • Table 63 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Dapsone (2021-2030) ($MN)
  • Table 64 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Dietary (2021-2030) ($MN)
  • Table 65 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Ready-to-eat Meals (2021-2030) ($MN)
  • Table 66 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Bakery Products (2021-2030) ($MN)
  • Table 67 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Pasta (2021-2030) ($MN)
  • Table 68 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 69 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 70 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Topical (2021-2030) ($MN)
  • Table 71 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 72 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Distribution channel (2021-2030) ($MN)
  • Table 73 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Retail stores (2021-2030) ($MN)
  • Table 74 Asia Pacific Dermatitis Herpetiformis Market Outlook, By E-Commerce (2021-2030) ($MN)
  • Table 75 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Pharmacies (2021-2030) ($MN)
  • Table 76 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Other Distribution channels (2021-2030) ($MN)
  • Table 77 South America Dermatitis Herpetiformis Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Dermatitis Herpetiformis Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 79 South America Dermatitis Herpetiformis Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 80 South America Dermatitis Herpetiformis Market Outlook, By Topical Corticosteroids (2021-2030) ($MN)
  • Table 81 South America Dermatitis Herpetiformis Market Outlook, By Sulfa Drugs (2021-2030) ($MN)
  • Table 82 South America Dermatitis Herpetiformis Market Outlook, By Dapsone (2021-2030) ($MN)
  • Table 83 South America Dermatitis Herpetiformis Market Outlook, By Dietary (2021-2030) ($MN)
  • Table 84 South America Dermatitis Herpetiformis Market Outlook, By Ready-to-eat Meals (2021-2030) ($MN)
  • Table 85 South America Dermatitis Herpetiformis Market Outlook, By Bakery Products (2021-2030) ($MN)
  • Table 86 South America Dermatitis Herpetiformis Market Outlook, By Pasta (2021-2030) ($MN)
  • Table 87 South America Dermatitis Herpetiformis Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 88 South America Dermatitis Herpetiformis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 89 South America Dermatitis Herpetiformis Market Outlook, By Topical (2021-2030) ($MN)
  • Table 90 South America Dermatitis Herpetiformis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 91 South America Dermatitis Herpetiformis Market Outlook, By Distribution channel (2021-2030) ($MN)
  • Table 92 South America Dermatitis Herpetiformis Market Outlook, By Retail stores (2021-2030) ($MN)
  • Table 93 South America Dermatitis Herpetiformis Market Outlook, By E-Commerce (2021-2030) ($MN)
  • Table 94 South America Dermatitis Herpetiformis Market Outlook, By Pharmacies (2021-2030) ($MN)
  • Table 95 South America Dermatitis Herpetiformis Market Outlook, By Other Distribution channels (2021-2030) ($MN)
  • Table 96 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 98 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 99 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Topical Corticosteroids (2021-2030) ($MN)
  • Table 100 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Sulfa Drugs (2021-2030) ($MN)
  • Table 101 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Dapsone (2021-2030) ($MN)
  • Table 102 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Dietary (2021-2030) ($MN)
  • Table 103 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Ready-to-eat Meals (2021-2030) ($MN)
  • Table 104 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Bakery Products (2021-2030) ($MN)
  • Table 105 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Pasta (2021-2030) ($MN)
  • Table 106 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 107 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 108 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Topical (2021-2030) ($MN)
  • Table 109 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 110 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Distribution channel (2021-2030) ($MN)
  • Table 111 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Retail stores (2021-2030) ($MN)
  • Table 112 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By E-Commerce (2021-2030) ($MN)
  • Table 113 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Pharmacies (2021-2030) ($MN)
  • Table 114 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Other Distribution channels (2021-2030) ($MN)